Heterocyclidene acetamide derivative

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 7910751
APP PUB NO 20080287428A1
SERIAL NO

11988659

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

A compound represented by formula (I′):—, or —S(O)r-; Q′ represents a heteroaryl group, a heteroarylalkyl group, a substituted aryl group, or an aralkyl group; Cycle moiety represents an aryl ring or a heteroaryl ring; and the wavy line represents an E-isomer or a Z-isomer), a salt of the compound, or a solvate of the compound or the salt. A pharmaceutical composition and a transient receptor potential type I (TRPV1) receptor antagonist each contain, as an active ingredient, at least one of the compound, a salt of the compound, and a solvate of the compound or the salt.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
MOCHIDA PHARMACEUTICAL CO., LTD.TOKYO71

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Akada, Yasushige Tokyo, JP 4 6
Amano, Ken-ichi Tokyo, JP 2 6
Hotta, Daido Tokyo, JP 3 16
Kamino, Tomoyuki Tokyo, JP 4 6
Kosuga, Naoto Tokyo, JP 3 16
Maeda, Yoshitaka Tokyo, JP 9 11
Satoh, Tsutomu Tokyo, JP 42 591
Uchida, Hideharu Tokyo, JP 3 11

Cited Art Landscape

Patent Info (Count) # Cites Year
 
PHARMACIA ITALIA S.P.A. (1)
2004/0204,477 Interaction inhibitors of tcf-4 with beta-catenin 15 2004
 
JAPAN TOBACCO INC. (1)
2006/0035,882 CONDENSED BENZAMIDE COMPOUNDS AND INHIBITORS OF VANILLOID RECEPTOR SUBTYPE 1 (VR1) ACTIVITY 12 2005
 
YAMANOUCHI PHARMACEUTICAL CO., LTD. (1)
5710150 Benzazepine derivative, pharmaceutical composition thereof, and intermediate thereof 8 1996
 
EASTMAN KODAK COMPANY (1)
6120964 2-(1,2-benzisothiazol-3(2H)-ylidene 1,1-dioxide)acetamides negative charge control agents for electrostatographic toners and developers 2 1999
 
Rhone-Poulenc Sante (1)
4977166 Benzopyran derivatives and pharmaceutical compositions containing them 13 1989
 
ASTELLAS PHARMA INC. (2)
6340678 4,4-difluoro-2,3,4,5-tetrahydro-1H-1-benzoazepine derivatives and drug compositions containing them 21 1999
2007/0167,444 Benzamide derivative or salt thereof 23 2004
 
MOCHIDA PHARMACEUTICAL CO., LTD. (2)
2008/0287,428 Novel Heterocyclidene Acetamide Derivative 2 2006
2010/0016,285 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE 5 2009
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
ABBVIE INC. (4)
8802711 TRPV1 antagonists 0 2012
8969325 TRPV1 antagonists 0 2012
8859584 TRPV1 antagonists 0 2012
8796328 TRPV1 antagonists 0 2013
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Sep 22, 2018
11.5 Year Payment $7400.00 $3700.00 $1850.00 Sep 22, 2022
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00